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Introduction
Ever since the discovery 20 years ago that the transforming
retroviral v-sis oncogene is derived from the platelet-derived
growth factor (PDGF) B chain gene, PDGF signaling has been
an interesting target for cancer treatment. In addition to its role
in autocrine growth stimulation of tumor cells, PDGF has also
been suggested to regulate tumor stroma fibroblasts and tumor
angiogenesis (Figure 1). The occurrence of clinically useful
PDGF receptor antagonists, like Glivec (STI571/Gleevec), now
allows for an evaluation of the importance of PDGF receptor
signaling in malignancies (Buchdunger et al, 1996; Capdeville
et al., 2002). This review summarizes the biology of PDGF and
discusses the role of PDGF receptor expression in different
tumor compartments. Two sets of recent findings are particular-
ly emphasized: the first set demonstrates clinical responses to
PDGF antagonists in autocrine settings, and the second set
presents beneficial effects of targeting PDGF receptors in the
tumor stroma in animal models.
Cell biological and physiological functions of PDGF
Four PDGF polypeptide chains have been identified, which
make up five dimeric PDGF isoforms: PDGF-AA, -AB, -BB, -CC,
and -DD (Heldin et al., 2002). The isoforms exert their cellular
effects through tyrosine kinase α- and β-receptors (Figure 1). All
PDGF isoforms, except PDGF-DD, induce PDGF α-receptor
dimerization, whereas PDGF-BB and -DD activate PDGF β-
receptor dimers. In addition, all isoforms except PDGF-AA acti-
vate both receptor types in cells coexpressing the α- and
β-receptors. Ligand-induced receptor dimerization causes
receptor autophosphorylation, whereafter intracellular signaling
pathways are activated by recruitment of SH2 domain-contain-
ing signaling molecules (e.g., c-Src, phospholipase C-γ, phos-
phatidyl-inositol-3′-kinase and the Grb2/Sos complex) to
specific phosphorylated tyrosine residues. Activation of these
pathways ultimately induces various cellular responses, includ-
ing cell proliferation, survival, and migration.
Targeting of the genes for PDGF-A and B chains, and for
the two receptors, has provided a detailed understanding of the
physiological functions of PDGF during development (Betsholtz
et al., 2001). Processes driven by the PDGF β-receptor include
pericyte recruitment to capillaries, development of smooth mus-
cle cells in vessels, and development of mesangial cells in the
kidney. Activation of PDGF α-receptors by PDGF-AA is required
for formation of alveolar smooth muscle cells, hair follicle devel-
opment, proper villus formation in the gut, and oligodendrocyte
development. In the adult, PDGF receptor signaling contributes
to wound healing through stimulation of, e.g., fibroblasts,
smooth muscle cells, and different inflammatory cells. PDGF β-
receptors also regulate the interstitial fluid pressure (IFP) and
thus potentially control transport from the vasculature into the
extracellular compartment of connective tissue (Heuchel et al.,
1999; Rodt et al., 1996).
PDGF antagonists
Several types of PDGF antagonists have been described, includ-
ing antibodies or DNA aptamers against ligands or the extracel-
lular part of the receptors, as well as low molecular weight
receptor kinase inhibitors (Östman and Heldin, 2001). Glivec
represents a kinase inhibitor for which there is already some clin-
ical experience (Capdeville et al., 2002); in addition to the PDGF
α- and β-receptors, Glivec also inhibits Kit, Abl, and Arg tyrosine
kinases. It is used in the treatment of chronic myelogenous
leukemia and gastrointestinal stromal tumors (GIST), character-
ized by overactivity of Abl and Kit, respectively, and has shown
rather mild side effects (Capdeville et al., 2002). Another PDGF
receptor antagonist that, despite having a broad specificity,
shows a tolerable toxicity profile and promising results from
phase I clinical trials is SU11248 (Mendel et al., 2003).
Autocrine PDGF receptor signaling
In certain malignancies, characteristic genetic alterations have
been identified which cause constitutive activation of PDGF
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Figure 1. The PDGF system is involved in multiple tumor-associated
processes
Upper: PDGF ligand binding specificity to PDGF receptors. Lower: PDGF
receptors are expressed by many different cell types within tumors, and
signaling from PDGF receptors can thus promote tumor progression in
various ways. Tumor cells, purple; endothelial cells, red; fibroblasts,
smooth muscle cells, and pericytes, green; extracellular matrix, brown.
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receptors and autocrine growth stimulation (Figure 2).
Amplification of the PDGF α-receptor gene occurs in a subset of
high-grade gliomas (Fleming et al., 1992; Kumabe et al., 1992),
and a ligand-independent deletion mutant of the PDGF α-
receptor fusion has also been characterized (Clarke and Dirks,
2003). Fusions of the PDGF β-receptor with proteins (e.g., the
transcription factor Tel or rabaptin-5, which causes dimerization
and thereby constitutive activation of the receptor kinase) have
been described in patients with chronic myelomonocytic
leukemia (CMML) (Golub et al., 1994; Magnusson et al., 2001).
Also, a constitutively active PDGF α-receptor fusion protein,
FIPL1-PDGFRα, has been identified in patients with idiopathic
hypereosinophilic syndrome (Cools et al., 2003a). Activating
point mutations and small deletions in the PDGF α-receptor
gene were also recently found in a subset of patients with GIST
(Heinrich et al., 2003). Finally, dermatofibrosarcoma protuber-
ans (DFSP) tumors are associated with translocations which
fuse the collagen 1A1 gene with the PDGF B chain and lead to
constitutive production of fusion proteins which are processed
to PDGF-BB (O’Brien et al., 1998; Shimizu et al., 1999; Simon
et al., 1997). In addition to these mutationally caused changes
in PDGF ligand and/or receptor expression, upregulation is also
well documented in, e.g., soft tissue sarcomas and gliomas
(reviewed in Östman and Heldin, 2001).
A series of studies have indicated that autocrine PDGF
receptor signaling contributes to the growth of glioma cells.
Also, the more recently identified PDGF isoforms, PDGF-CC
and -DD, have been implied in autocrine glioma signaling
(LaRochelle et al., 2002, Lokker et al., 2002). Inhibition of
growth of cultured glioma cells has been achieved with different
PDGF antagonists, including dominant negative forms of PDGF
or PDGF receptors (Shamah et al., 1993; Strawn et al., 1994).
More recently, intracranial growth of gliomas in mice was also
shown to be sensitive to treatment with STI571 (Kilic et al.,
2000). A causative role for autocrine PDGF receptor signaling in
gliomas is also indicated by the development of gliomas after in
vivo PDGF B chain gene transfer to neuroglial progenitor cells
(Dai et al., 2001; Uhrbom et al., 1998).
Together, these studies have led to the
initiation of different clinical trials from
which results are still pending.
Clinical responses to PDGF
antagonists in CMML and DFSP
In a pioneering study, Apperley et al.
recently treated four CMML patients, all
with PDGF β-receptor-activating translo-
cations, with 400 mg per day of STI571
(Apperley et al., 2002). Normalized
peripheral blood count was observed
after one week of treatment in all four
patients. In three of the patients, t(5;12)
translocation-positive cells were undetectable after 12 weeks of
treatment, whereas the fourth patient required 36 weeks of
treatment before translocation-positive cells were no longer
seen. The responses persisted after 9 to 12 months of treat-
ment. In addition to this study, a case report has also been pub-
lished which describes rapid response and molecular remission
in another patient with CMML (Magnusson et al., 2002).
Recent case reports have described reduction in tumor vol-
ume in patients with DFSP (Maki et al., 2002; Rubin et al.,
2002).Two weeks of treatment with 400 mg STI571 per day of a
patient with an unresectable tumor reduced the hypermetabolic
tumor uptake of 18F-FDG to background levels. After two addi-
tional weeks of treatment, tumor volume was reduced by 75%,
allowing tumor resection; no viable tumor cells were seen in the
resected specimen. Similar observations of reduction in tumor
mass have been observed in other DFSP patients (M.C.
Heinrich, personal communication). However, not all DFSP
patients respond to treatment, since rapid progression and sub-
sequent death, after a transient response to STI571, have also
been reported (Maki et al., 2002).
Inhibition of PDGF receptor signaling in tumor stroma
enhances the therapeutic effects of chemotherapy in
animal tumor models
Paracrine stimulation by PDGF can affect tumor stroma recruit-
ment and growth, as evidenced by studies showing an
increased rate or incidence of tumor formation upon transfec-
tion of PDGF into receptor-negative tumor cell lines (Forsberg
et al., 1993; Skobe and Fusenig, 1998). Furthermore, the
desmoplastic response of breast carcinoma cells, characterized
by excessive production of extracellular matrix and proliferation
of myofibroblast-like cells, has been shown to be dependent on
PDGF (Shao et al., 2000). Although no studies so far have
demonstrated antitumor effects after targeting of stromal PDGF
antagonists, the effects of combining stroma-targeting PDGF
antagonists with, for example, antiangiogenic drugs merits fur-
ther investigations. The clinical potential of such approaches is
F O C U S
Figure 2. Examples of genetic alterations that
give rise to dysregulated PDGF receptor signal-
ing in different tumors
Examples of malignancies in each category are
given in italics. It is not fully elucidated whether
the activation of amplified or point-mutated
PDGF receptors is dependent on PDGF
ligand(s). Active PDGF receptor kinase, yellow
star; PDGF ligand, green; dimerization domain
not derived from the PDGF receptor, red.
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underscored by the recent observation that more than 50% of
solid tumors on an NCI tumor tissue array express PDGF β-
receptors in the tumor stroma (T.S., unpublished data).
The notion that PDGF receptors in tumor stroma are indeed
candidate targets for cancer therapy has recently found support
from studies where PDGF receptor inhibitors were used in ani-
mal tumor models displaying expression of PDGF receptors
exclusively in stromal fibroblasts and perivascular cells. As
expected, no effects on tumor growth rate were observed by
monotherapy with PDGF receptor inhibitors. In contrast, striking
results were obtained when PDGF antagonists were combined
with chemotherapy (Pietras et al., 2002). The combined treat-
ment resulted in an increased efficacy, corresponding roughly
to a 3-fold increase in the dose of the cytotoxic drug, and tran-
spired without any apparent escalation of toxicity.The enhanced
therapeutic response occurred in parallel to a tumor-selective
increase in drug uptake (Pietras et al., 2002, 2003). Following
PDGF receptor inhibition, the tumor content of the cytotoxic
drugs paclitaxel and epothilone B, as well as of the tracer com-
pound 51Cr-EDTA, increased by as much as 4-fold. In contrast,
tumor angiogenesis and tumor cell sensitivity to chemotherapy
were unchanged by administration of PDGF antagonists and
could not account for the beneficial effects.The observed thera-
peutic synergy is thus best explained by the increased tumor
uptake of cytotoxic drugs.
The increased interstitial fluid pressure (IFP) in solid tumors
constitutes one of many hindrances for drug delivery (Jain,
2001). A possible reason for the enhanced transvascular trans-
port occurring upon blocking of PDGF receptor signaling is thus
offered by studies showing a reduction in tumor IFP after treat-
ment with PDGF antagonists (Figure 3) (Pietras et al., 2001,
2002). Further support for this hypothesis is provided by the
observations that the kinetics of the effects of PDGF antago-
nists on tumor IFP are identical to the time frame in which aug-
mented drug transport is observed (K.P., unpublished data).
Additional mechanistic studies are clear-
ly warranted to further investigate the
mechanism(s) underlying the PDGF
antagonist-induced increased transvas-
cular transport. Furthermore, only clini-
cal studies will reveal if the drug uptake
effects also occur in human tumors and,
if that is the case, if these effects will be
able to override other resistance mecha-
nisms like expression of multidrug resis-
tance genes and/or p53 mutations.
PDGF receptors as potential targets
for antiangiogenic therapy
Most solid tumors display expression of
PDGF receptors on endothelial or
perivascular cells (Hermanson et al.,
1988; Sundberg et al., 1993; Pietras et
al., 2003). A possible role of PDGF
receptor signaling in angiogenesis is implied by proangiogenic
activity of PDGF-AB and -BB in the chick chorioallantoic mem-
brane assay (Risau et al., 1992), and of PDGF-AB, -BB, and -
CC in the mouse corneal pocket assay (Cao et al., 2002).Tumor
angiogenic effects of PDGF-DD were also recently demonstrat-
ed (Li et al., 2003).
Concerning the mechanism of the proangiogenic effects of
PDGF, there is strong evidence for an important role of PDGF in
pericyte recruitment (Hellström et al., 1999). PDGF receptor
signaling might therefore contribute to tumor angiogenesis by
increasing pericyte recruitment and vessel maturation.
Experimental support for this notion was recently obtained with
the demonstration of PDGF-dependent recruitment of pericytes
to tumor vessels in a mouse model of glioma (Guo et al. 2003).
Upregulation of PDGF receptors on tumor endothelial cells
under special circumstances has also been described. In a
mouse model of prostate cancer bone metastasis, PDGF β-
receptor expression was observed on endothelial cells of
tumors growing in the bone, but not on endothelial cells of nor-
mal bone or of tumors growing in surrounding muscle (Uehara
et al., 2003). Interestingly, antiangiogenic effects, including
increased endothelial cell apoptosis and reduced microvessel
density, were observed in bone lesions after treatment with
STI571.
Perspectives
Encouraging effects of treatments with PDGF receptor
inhibitors have been obtained in malignancies where PDGF
autocrine stimulation or PDGF receptor activation is caused by
specific mutational events. Whether patients carrying tumor
types in which PDGF and/or PDGF receptors are overex-
pressed as a consequence of epigenetic mechanisms, e.g. as
frequently occurs in glioblastoma, will also benefit from treat-
ment with PDGF antagonists remains to be established. The
continued search for mutations in PDGF ligands and receptors
F O C U S
Figure 3. Schematic illustration of the transvas-
cular transport in tumors and normal tissue with
or without treatment with PDGF receptor
inhibitors
Active PDGF receptor kinase, yellow star; inhibit-
ed PDGF receptor kinase, red cross; cytotoxic
drug, yellow circle.
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is highly motivated and likely to reveal additional patient subsets
that could benefit from treatment with PDGF antagonists.
Continued identification of additional PDGF receptor inhibitors
for Glivec-resistant PDGF receptor variants, as described in this
issue of Cancer Cell, is also highly warranted (Cools et al.,
2003b). Improved methods for detection of activated PDGF
receptors would be most useful for screens of tumor arrays to
identify tumor subsets, which should be selected for the more
work-intensive genetic analyses. Development of activation-
specific antibodies is thus an important goal. In this regard, the
successful development of activation-specific EGF receptor
antibodies, suitable for immunohistochemical applications, is
encouraging (Albanell et al., 2002; Baselga et al., 2002).
The findings of enhanced therapeutic response after inhi-
bition of PDGF receptors in tumor stroma dramatically broad-
en the spectrum of tumor types for which treatment with PDGF
antagonists could be considered. However, the outcome of
clinical studies exploring this concept will be highly dependent
on the recruitment of the optimal patient subset. Also for this
purpose, activation-specific receptor antibodies would be use-
ful, as well as surrogate markers for identification of patients
displaying changes in tumor uptake of drugs upon PDGF
receptor inhibition.
The selective upregulation of PDGF receptors on endothe-
lial cells in the mouse model of prostate cancer bone metas-
tases should stimulate further study of expression of PDGF
receptors on tumor endothelial cells.The frequent expression of
PDGF receptors on perivascular cells also suggests as yet
unexploited therapeutic opportunities. The well-documented
effect of PDGF on pericyte recruitment points to the possibility
of combining antiendothelial agents, like vascular endothelial
growth factor receptor inhibitors, with pericyte-targeting PDGF
antagonists. Finally, it has been shown that bone marrow-
derived cells contribute to the angiogenic switch in tumors
(Coussens et al., 2000). PDGF receptor inhibitors can possibly
inhibit this process, since PDGF stimulates migration and prolif-
eration of macrophages (Siegbahn et al., 1990).
In summary, there are several possible indications for use of
PDGF antagonists in tumor treatment. Additional preclinical and
clinical studies are highly warranted to explore these possibilities.
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